CF5B Can Fite BioPharma

Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019

PETACH TIKVA, Israel--(BUSINESS WIRE)--

Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will share insight into the Company’s recent developments during an investor webinar on Monday, November 25, 2019 at 11:00 a.m. ET. A live Q&A session with Dr. Fishman will follow her presentation.

To join the Can-Fite webinar, please register via the following link:

The webinar will be accessible through the News/Events section of Can-Fite’s website at , where it will also be archived for a period of time.

Questions can be pre-submitted to or during the event.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and the Company is investigating additional compounds, targeting A3AR, for the treatment of sexual dysfunction. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. For more information please visit: .

EN
21/11/2019

Underlying

CF5BCan Fite BioPharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Can Fite BioPharma

 PRESS RELEASE
Free
CF5B Can Fite BioPha...

Positive Results from Osteoarthritis Clinical Study in Dogs Reported b...

RAMAT GAN, Israel--(BUSINESS WIRE)-- Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix reported positive results in an osteoarthritis multicenter clinical study in dogs treated with Piclidenoson. , Can-Fite’s veterinary commercialization partner which is covering all costs associated with veterinary clinical development, concluded successfully the study interim analysis. After Piclidenoson proved efficacious, Vetbio...

June 28, 2024 1 EN
 PRESS RELEASE
Free
CF5B Can Fite BioPha...

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer an...

PETACH TIKVA, Israel--(BUSINESS WIRE)-- (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating anti-inflammatory, anti-cancer, metabolic and insulin resistance. Namodenoson increases adiponectin production in pre-clini...

June 24, 2024 1 EN
 PRESS RELEASE
Free
CF5B Can Fite BioPha...

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer ...

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received an approval from the Institutional Review Board (IRB) of Rabin Medical Center, a leading medical institution in Israel where the study will be conducted. The approved protocol has been submitted now to the Ministry of Health (MOH). “This Phase IIa study is designed as an open-label one, enabling us to assess the safety and potential efficacy of Nam...

June 10, 2024 1 EN
 PRESS RELEASE
Free
CF5B Can Fite BioPha...

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

RAMAT GAN, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced an update on the status of its oncological lead drug candidate, Namodenoson in the treatment of advanced liver cancer. The Phase 3 pivotal study now has 31 recruiting medical centers in Europe, Israel and the US. Namodenoson has Orphan Drug status with both the U.S. Food and Drug Administration (FDA) and European Medicines Agency, as well as Fast Track ...

June 5, 2024 1 EN
 PRESS RELEASE
Free
CF5B Can Fite BioPha...

Independent Scientists Published a Review Article Demonstrating That C...

RAMAT-GAN, Israel--(BUSINESS WIRE)-- (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported that the International Journal of Molecular Sciences published a scientific review by independent scientists summarizing >50 publications from scientists all over the world stating that piclidenoson and namodenoson have a positive effect on heart diseases (). According to the review, both piclidenoson and namodenoson induced in pre-clinical in vivo studies beneficial outcom...

May 29, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch